(Q40530013)

21 September 2017

title

Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318. (English)

1 reference

21 September 2017

main subject

multiple drug resistance

1 reference

5

1 reference

21 September 2017

Li-ming Chen

1

1 reference

21 September 2017

Yong-ju Liang

2

1 reference

21 September 2017

Ji-wu Ruan

3

1 reference

21 September 2017

Yan Ding

4

1 reference

21 September 2017

Zhi Shi

6

1 reference

21 September 2017

Lian-Quan Gu

7

1 reference

21 September 2017

Xiao-ping Yang

8

1 reference

21 September 2017

Li-wu Fu

9

1 reference

21 September 2017

publication date

1 August 2004

1 reference

Journal of Pharmacy and Pharmacology

21 September 2017

published in

1 reference

21 September 2017

volume

56

1 reference

21 September 2017

issue

8

1 reference

21 September 2017

page(s)

1061-1066

1 reference

Modulation of MDR/MRP by wild-type and mutant p53.

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1211%2F0022357043879

P-glycoprotein, multidrug resistance and protein kinase C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357043879

The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357043879

Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357043879

The role of topoisomerase II alpha and beta in drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357043879

Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357043879

Multidrug resistance: molecular mechanisms and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357043879

Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357043879

Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357043879

Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357043879

Multidrug resistance transporters and modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357043879

Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357043879

21 January 2018

Identifiers

DOI

10.1211/0022357043879

1 reference

21 September 2017

1 reference